![\"](\"https:\/\/techma.bakertilly.es\/wp-content\/uploads\/2019\/07\/doctor-reviewing-tablet-300x200.jpg\" "\\"")
<\/p>\nDevicare, part of the healthcare sector, has developed an innovative solution for the treatment of kidney stones. We analyse its recent \u20ac1.6m round as well as other relevant corporate transactions in the sector.<\/p>\n
<\/p>\n
Devicare<\/a> is a Spanish company specialising in urological therapeutic solutions<\/strong>. It currently has a staff of 25 people, a scientific and clinical advisory board and strategic alliances with leading organisations.<\/p>\n It has recently developed a solution for the non-surgical treatment of renal lithiasis or kidney stones, called Lit-Control, with commercial agreements in 30 countries with different pharmaceutical companies. This medical solution consists of three nutraceuticals to modulate the pH of the patient's urine and inhibit the growth of different types of crystals, and a medical device to monitor the urinary pH.<\/p>\n It has recently closed the largest round<\/a> de\u00a0crowdfunding<\/em>\u00a0health care in Spain of more than 1,6M\u20ac<\/strong> through Capital Cell to accelerate its growth, primarily the entry into new markets and finalise the development of a\u00a0app<\/em>\u00a0for Lit-Control.<\/p>\n This biotech company<\/strong> has innovated in recombinant molecule production technologies<\/strong>. In particular, it has invented and patented a robotic production platform that does not require complex and costly bioreactors. In this way, Algenex<\/a> has succeeded in simplifying the process, improving productivity and reducing the costs associated with setting up a biologics factory by up to 95%.<\/p>\n With the latest round of 4M\u20ac<\/strong> The new company has closed and the appointment of top professionals will seek to expand its product and achieve a wider reach through its commercial roll-out.<\/p>\n It is a company specialising in the repositioning of drugs to treat rare diseases of the nervous system<\/strong>. It currently has a theoretical company value of more than 200 million euros, guaranteed by independent experts.<\/p>\n Som Biotech<\/a> has managed to raise 7M\u20ac<\/strong> in a round of funding, which will go towards finalising the project they are working on to test the efficacy and safety of an innovative treatment for the choreic movements associated with Huntington's disease.<\/p>\n<\/span>Other relevant operations in the sector include:<\/strong><\/span><\/h2>\n
<\/span>ALGENEX<\/strong><\/span><\/h3>\n
<\/span>SOM BIOTECH<\/strong><\/span><\/h3>\n
<\/span>CUBIQ FOODS<\/strong><\/span><\/h3>\n